Xenogen Corp

Xenogen — Merger or Acquisition (February 2006)

9 slides from Xenogen's merger presentation, Feb 16, 2006

  1. Slide 1: Transforming Discovery with Innovative Technologies

    Slide 1: Transforming Discovery with Innovative Technologies

    Transforming Discovery with Innovative Technologies February 14, 2005 Happy Valentines Day!

  2. Slide 2: Discovery Value Chain

    Slide 2: Discovery Value Chain

    Relevance—=>>——» Discovery Value Chain SS In Vitro Y¥ ole. +Fluidics & Automation *Biophotonics Detection Detection +Assays: +Molecular Biology *Biochemistry + Services +Services W Caliper...

  3. Slide 3: Overall strategic, structural and financial fit assessment

    Slide 3: Overall strategic, structural and financial fit assessment

    inwaorevanee a re ace eT TNT Imaging relevance ‘3 The Ceacpicn a Taneen ear acbp nelaeun Propeey + andl Po chinese ig Patel pptcalons bona * a See, a LE ESN RTS SORT PATER Atocve Teng ColpersTaI0G BOE + enimodrineraet cnemar aa ‘Seng atrmarel polenta + Poa obi Sc anu am aA Serves average * TS STE DU

  4. Slide 4: Significant upside potential exists in several areas

    Slide 4: Significant upside potential exists in several areas

    igniticant upside potential exists In seve! areas LPTA and ZebBio technology combined, Caliper product ZebraBio and NovaScreen Services technology Applications strategy : Accounts J Revenues per account YW Caliper,

  5. Slide 5: Caliper Status

    Slide 5: Caliper Status

    Caliper Status > Revitalized financials with a revitalized strategy / momentum » Solid management and operational team with capacity / desire for growth > Strong market reach into Pharma and Biotech with track record for commercializing transformative technologies into profitable and sustainable pro

  6. Slide 6: Opportunity: Merge C and Z

    Slide 6: Opportunity: Merge C and Z

    Opportunity: Merge C and Z > Through unique senior level Pharma/Biotech relationships, we have identified a keen emerging interest in Biomarker research and Imaging technologies. > Today, C has a minimal, but emerging position in Biomarker research, but lacks a position in the rapidly expanding imag

  7. Slide 7: Opportunity: Merge C and Z - Continued

    Slide 7: Opportunity: Merge C and Z - Continued

    tinued pportunity: Merge C and Z - C » A carefulprocess has resulted in a unique opportunity to merge Z and C now. Transaction economics are compelling to both sets of owners. » C has the demonstrated experience and capabilities to integrate Z and, based on the diligence learnings, is confident of s

  8. Slide 8: C & Z Merger Catalyzes Our Strategy

    Slide 8: C & Z Merger Catalyzes Our Strategy

    C & Z Merger Catalyzes Our Strategy M&A screens have yielded a small number of actionable opportunities » Filter: Strategic fit, cost synergies, under valued, insufficient critical mass >» Z Merger: Super charges top line growth on larger base Breakthrough critical mass valuation Improves trajectory

  9. Slide 9: Value drivers for life sciences companies are improved by joining forces

    Slide 9: Value drivers for life sciences companies are improved by joining forces

    Value drivers for life sciences companies are improved by joining forces ie) ic) ° ° eo) ° ° 3 e @ ° Qo i) ° Grn | © © e ‘YW caliper.

Source: SEC EDGAR · DEFA14A filed Feb 16, 2006

More decks from Xenogen Corp